Gain Therapeutics Q1 net loss $0.13/sh; Phase 1b biomarker data support GT-02287

Gain Therapeutics, Inc.

• Q1 net loss $0.13 per share vs $0.16; R&D $2.8M, G&A $2.6M; cash $16.5M as of March 31, 2026.
• Phase 1b extension for GT-02287 shows GluSph in CSF decreased 81% in elevated baseline participants after 90 days.
• MDS-UPDRS scores stable over 150 days; 14 of 16 participants completed five months of dosing as of March 2026.
• Expecting FDA IND clearance for GT-02287 in Q2 2026 and Phase 2 start in Q3 2026.
• New allosteric modulator GT-04686 ready for IND-enabling studies; presented at AD/PD 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.